칼슘채널차단제, 레닌-안지오텐신시스템 차단제, 이뇨제의 잠재적 간독성 평가
The Evaluation of Potential Hepatotoxicity by Calcium Channel Blockers, Renin-Angiotensin System Blockade and Diuretics
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background : Hypertension is treated with both lifestyle modification and pharmacotherapy. The Seventh Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7), published in 2003,provides a streamlined management approach to hypertension for the primary care physician. The JNC-7 is the gold standard also in Korea. According to the JNC-7, special therapeutic considerations are recommended for high-risk individuals with compelling indications. The presence of compelling indications in any given patient should be considered when selecting specific pharmacotherapy to treat hypertension. However, in patients with compelling indications, it is unknown that hepatotoxicity is caused by Calcium Channel Blocker (CCB), one of 1st anti-hypertensive drugs. Now,the CCB is the most used 1st anti-hypertensive drug in Korea Therefore, we evaluated the changes in blood liver function parameters (ALT, AST, Total bilirubin, serum albumin) for the study group. Methods : We randomly collected and retrospectively analyzed Electronic Medical Record data (n=28,788) of patients, and who took calcium channel blockers(non-dihydropyridines; diltiazem, verapamil, dihydropyridines; amlodipine, barnidipine, benidipine, clinidipine, efonidipine,felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine), with having liver function tests (LFTs)from July 1st 2009 to June 30th 2010 at the Seoul National University Hospital in Korea. Control groups are two antihypertensive agents: RAS blockade (ARB; candesartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, ACE-I;cilazapril, enalapril, fosinopril, imidapril, perindopril, ramipril) and, Diuretics (loop; furosemide, torsemide, thiazide;hydrochlorothiazide[HCTZ], indapamide). Patients not having LFT results at these three standard points of time(baseline,during, medication, and after finishing medication) were excluded. The collected data were analyzed by using the SPSS (Version12.0) and Microsoft Excel (Version2007). Results : 711 patients who were treated CCB (297), RAS blockade (232) or Diuretics (182) monotherapy were selected for the study. In selected patients, liver damage degree(changes of each LFTs value) was higher in diuretics group than other groups, followed by RAS blockade and CCB. In diuretics group’s was loop-diuretics group was higher than thiazide-diuretics group. In CCB group, Nondihydropyridine-CCB’s damage degree was higher than Dihydropyrine-CCB’s that. Conclusions : Despite the limitations due to the retrospective study, among patients with abnormal LFTs, the use of CCBs led to a less liver damage than other 1st anti-hypertensive agents. It can be recommended CCBs as one of the initial treatments of hypertension in patients with liver disease.
Abstract
Background : Hypertension is treated with both lifestyle modification and pharmacotherapy. The Seventh Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7), published in 2003,provides a streamlined management approach to hypertension for the primary care physician. The JNC-7 is the gold standard also in Korea. According to the JNC-7, special therapeutic considerations are recommended for high-risk individuals with compelling indications. The presence of compelling indications in any given patient should be considered when selecting specific pharmacotherapy to treat hypertension. However, in patients with compelling indications, it is unknown that hepatotoxicity is caused by Calcium Channel Blocker (CCB), one of 1st anti-hypertensive drugs. Now,the CCB is the most used 1st anti-hypertensive drug in Korea Therefore, we evaluated the changes in blood liver function parameters (ALT, AST, Total bilirubin, serum albumin) for the study group. Methods : We randomly collected and retrospectively analyzed Electronic Medical Record data (n=28,788) of patients, and who took calcium channel blockers(non-dihydropyridines; diltiazem, verapamil, dihydropyridines; amlodipine, barnidipine, benidipine, clinidipine, efonidipine,felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine), with having liver function tests (LFTs)from July 1st 2009 to June 30th 2010 at the Seoul National University Hospital in Korea. Control groups are two antihypertensive agents: RAS blockade (ARB; candesartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, ACE-I;cilazapril, enalapril, fosinopril, imidapril, perindopril, ramipril) and, Diuretics (loop; furosemide, torsemide, thiazide;hydrochlorothiazide[HCTZ], indapamide). Patients not having LFT results at these three standard points of time(baseline,during, medication, and after finishing medication) were excluded. The collected data were analyzed by using the SPSS (Version12.0) and Microsoft Excel (Version2007). Results : 711 patients who were treated CCB (297), RAS blockade (232) or Diuretics (182) monotherapy were selected for the study. In selected patients, liver damage degree(changes of each LFTs value) was higher in diuretics group than other groups, followed by RAS blockade and CCB. In diuretics group’s was loop-diuretics group was higher than thiazide-diuretics group. In CCB group, Nondihydropyridine-CCB’s damage degree was higher than Dihydropyrine-CCB’s that. Conclusions : Despite the limitations due to the retrospective study, among patients with abnormal LFTs, the use of CCBs led to a less liver damage than other 1st anti-hypertensive agents. It can be recommended CCBs as one of the initial treatments of hypertension in patients with liver disease.
참고문헌 (35)
- 2010 국민건강통계:국민건강영양조사 (KNHANES), "보건복지부", ~ (2011)
- "NCHS. Health" (2010)[URL]
- Martindale, "The complete drug reference. 34th ed", pp.2768~ (2002), Phamaceutical Press
- Mary Anne Koda-Kimble, "Applied Therapeutics : The Clinical Use of Drugs Ninth Edition" (2008)
- Mancia Giuseppe, "ESHESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension", Journal of Hypertension, 25(9), pp.1751~1762 (2007)
- NICE, "NICE Clinical Guideline. 127, 36", ~ (2011)
- 성예나, "고혈압 환자의 혈압강하제 처방양상- 외래 처방전을 중심으로", 한국임상약학회지, 19(2), pp.167~179 (2009), 한국임상약학회
- Chobanian AV, "Seventh Report of the Joint National Committee on Prevention", Hypertension, 42(6), pp.1206~1252 (2003)
- Shivakumar Chitturi, "Hepatotoxicity of Commonly Used Drugs: Nonsteroidal Anti-Inflammatory Drugs, Antihypertensives, Antidiabetic Agents, Anticonvulasants, Lipid-Lowering Agents, Psychotropic Drugs", Seminars in Liver Disease, 22(2), pp.169~183 (2002)
- Dahlof B, "Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol", Lancet, 359, pp.995~1003 (2002)
- Dahlof B, "Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo- Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial", Lancet, 366, pp.895~906 (2011)
- Fox KM, "Efficacy of perindopril in reduction of cardiovascular events among patients with stable oronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial(the EUROPA study)", Lancet, 362, pp.782~788 (2003)
- Nissen SE, "Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial", JAMA, 292, pp.2217~2225 (2004)
- The antihypertensive and lipid-lowering treatment to prevent heart attack trial Officers and Coordinators for the ALLHAT Collaborative Research Group, "Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)", JAMA, 288, pp.2981~2997 (2002)
- Turnbull F, "Effects of different blood-pressure lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials", Lancet, 362, pp.1527~ (2003)
- Weber MA, "Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial", Lancet, 363, pp.2049~2051
- Yusuf S, "Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators", N Engl J Med, 342, pp.145~153 (2004)
- De Luis DA, "Toxicidad hepaica y amlodipine", Medicina Clinica, 110, pp.638~639 (1998)
- Odeh M, "Verapamil-associated liver injury", Harefuah, 134, pp.36~37 (1998)
- Romano G, "Lethal diltiazem poisoning", J Anal Toxicol, 26, pp.374~377 (2002)
- Shallcross H, "Fatal renal and hepatic toxicity after treatment with diltiazem", Br Med J, 295, pp.1236~1237 (1997)
- Kumar KL, "Verapamil-induced hepatotoxicity", West J Med, 160, pp.485~486 (1994)
- Toft E, "Diltiazem-induced granulomatous hepatitis", Histopathology, 18, pp.474~475 (1991)
- Babany G, "Alcoholic-like liver lesions induced by nifedipine", Hepatology, 9, pp.252~255 (1989)
- Nunes AC, "Fosinopril-induced prolonged cholestatic jaundice and pruritus: first case report", Eur J Gastroenterol Hepatol, 13, pp.279~282 (2001)
- Rahmat J, "Captoprilassociated cholestatic jaundice", Ann Intern Med, 102, pp.56~58 (1995)
- Rosellini SR, "Hepatic injury related to enalapril", Gastroenterology, 97, pp.810~ (1989)
- Todd P, "Enalapril-related cholestatic jaundice", J R Soc Med, 83, pp.271~272 (1990)
- Hagley MT, "Hepatotoxicity asssociated with angiotensin-converting enzyme inhibitors", Ann Pharmacother, 27, pp.228~231 (1993)
- Jeserich M, "Acute liver failure due to enalapril", Herz, 25, pp.689~693 (1990)
- Ohyama T, "Azelnidipine is a calcium blocker that attenuates liver fibrosis and may increase antioxidant defence", Br J Pharmacol, 165(4b), pp.1173~1187 (2012)
- Khan NA, "Protective effects of amlodipine on mitochondrial injury in ischemic reperfused rat heart", J Environ Biol, 33(3), pp.591~595 (2012)
- Oseasohn R, "Clinicopathologic study of thirty-three fatal cases of Asian influenza", N Engl J Med, 260(11), pp.509~518 (1959)
- Ray CG, "The use of intravenous ribavirin to treat influenza virusassociated acute myocarditis", J Infect Dis, 159(5), pp.829~836 (1989)
- Nolte KB, "Influenza A virus infection complicated by fatal myocarditis", Am J Forensic Med Pathol, 21(4), pp.375~379 (2000)